Prepared by Dr. David Miller, FRM, Head of Quantitative Research | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-4B8D25D5-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns bestex research a Bullish outlook for the next quarter. Key drivers include a P/E of 69.8x, 19.3% revenue expansion, and an RSI of 63 suggesting a neutral-bullish phase. We define critical support at $2380.5 and resistance at $2909.5.
Rating: Buy | Target Price: $2988.85 | Next Earnings: Jun 27
Download Full PDF Report
Ichimoku Cloud flipped bullish with the lagging span breaking above, confirming trend shift.
On-chain money flow shows 25%% increase in smart money index, reinforcing the technical setup.
MACD printed a Bullish Crossover as the 50-day SMA turned positive 21 days ago.
EPS of $37.89 reveals resilient earnings quality. DuPont analysis highlights operating leverage as the key ROE driver.
Relative to Healthcare peers, bestex research sits at the 56th percentile in valuation, offering a potential value opportunity.
Free cash flow conversion remains robust at 86%, supporting the 0.39% dividend and buybacks.
Options skew is toward call at the 2539.2 strike, positioning for a directional move.
Short float at 7.6% is below the sector average, reducing squeeze risk. Institutional ownership is 57%.
Beta of 1.77 suggests bestex research is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $2645 | $2512.75 |
| Market Cap | $3.76B | $3.76B |
| P/E Ratio | 69.8x | 59.3x |
| EPS (TTM) | $37.89 | $34.1 |
| Dividend Yield | 0.39% | 0.3% |
| Revenue Growth | 19.3% | 11.6% |
| Target Price | $2988.85 | - |
| Beta | 1.77 | 1.00 |